The UK and US have signed a key commercial pact that will keep no levies on British medicine exports being sold in the US market.
Agreement Details of the Accord
As part of the deal, the UK has committed to increase spending on pharmaceuticals through the public health system. This commitment ensures that duties on these key goods will be held at nothing for a duration of three years.
This deal follows recent statements to dramatically increase import taxes on patented drug imports, with increases floated reaching double the cost.
"This arrangement between the United Kingdom strengthens the international landscape for innovative medicines and establishes long-overdue balance to U.S.–U.K. medicine commerce," a statement said.
Commercial Significance
Medicines represent one of the Britain's largest export categories to the America, which is clearly the primary market for leading UK drugmakers.
Statistics indicate that in the 12 months leading up to the third quarter, the UK exported pharmaceutical products valued at over eleven billion pounds to the US. This value accounted for nearly one-fifth of total UK exports in that timeframe.
"This guarantee protects jobs, boosts funding and facilitates the UK to establish itself as a international leader for life sciences," a minister stated.
Detailed British Pledges
The pact includes several specific changes from the British government:
- Price Threshold Increase: The UK will increase the cost ceiling at which it judges new treatments to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a goal to double total health service expenditure on treatments from 0.3% of the national economy to 0.6% over the following ten-year period.
- Refund Ceiling: The amount drug companies must pay back to the NHS to control costs will be capped at fifteen percent. Last year, refunds topped twenty percent.
Broader Context
This agreement comes amid a ongoing row between the sector and the ministers over medicine costs and regulatory access.
The disagreement were heightened by assertions that American patients were charged a premium for the same drugs than consumers in the UK and Europe.
Over the last 18 months, several major drug company projects in the UK have been halted or scrapped, while substantial investments have been pledged toward US facilities.
One official acknowledged that the NHS needed to increase expenditure on treatments, noting that its spending on drugs had decreased as a percentage of its resources over the previous ten-year period.
